logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
D

David Pérol

centre leon berard
H指数:49
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Chemotherapy outcomes in human epidermal growth factor receptor 2-low, hormone receptor-positive metastatic breast cancer: Insights from the French multicenter ESME database

人表皮生长因子受体2低表达、激素受体阳性转移性乳腺癌的化疗结局：来自法国多中心ESME数据库的见解

Breast
IF7.9
2026-09-270
OA
William Jacot; Pauline Macouillard; Suyuan Zhang; Danalyn Byng; Shannon Hunter; Vincent Massard; Jean-Sébastien Frenel; David Pérol; Etienne Brain; Audrey Mailliez; Thomas Bachelot; Monica Arnedos; Lise Bosquet; Véronique Diéras
Is pembrolizumab as safe and efficient as neoadjuvant treatment in localized dMMR/MSI esophagogastric cancers? Results from the IMHOTEP phase II study

帕博利珠单抗作为局部dMMR/MSI食管胃癌的新辅助治疗是否安全有效？——IMHOTEP II期研究的结果

ESMO Open
IF8.3
2026-09-090
OAAI
C. Coutzac; A. Zaanan; A. de Montfort; E. Soularue; R. Cohen; S. Le Sourd; G. Piessen; V. Hautefeuille; M. Ben Abdelghani; E. Blanc; M. Svrcek; E. Samalin; D. Pérol; C. de la Fouchardière
Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial

根据PIK3CA突变状态评估buparlisib在复发或转移性头颈鳞状细胞癌中的疗效：一项多中心II期临床试验

Oral Oncology
IF3.9
2026-05-130
PRE
Thibault Gauduchon; Laurence Digue; Céline Ferlay; Isabelle Treilleux; Qing Wang; Valéry Attignon; Gautier Lefebvre; Nuria Kotecki; Amaury Daste; Caroline Even; Sophie Couchon-Thaunat; Aurélie Guyennon; Frédéric Peyrade; Didier Cupissol; Benoît You; Christophe Le Tourneau; Séverine Tabone-Eglinger; Gwenaelle Garin; David Pérol; Jérome Fayette
Cabozantinib in Patients with Non-Locally Pretreated Brain Metastases from Renal Cell Carcinoma: Results of the Multicenter Phase II Trial CABRAMET

卡博齐坦在非局部预处理的肾细胞癌脑转移患者中的疗效：CABRAMET多中心II期试验结果

European Journal of Cancer
IF7.1
2026-04-010
PRE
Sylvie Negrier; Loïc Mourey; Cécile Dalban; Marine Gross-Goupil; Aude Fléchon; Bernard Escudier; Philippe Barthélémy; Stéphane Oudard; Emeline Colomba; Constance Thibault; Alain Ravaud; Christine Chevreau; Helen Jane Boyle; Ellen Blanc; Sylvie Chabaud; David Pérol; Laurence Albiges; Ronan Flippot
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohort

CDK4/6抑制剂治疗后疾病进展的HR阳性/HER2阴性转移性乳腺癌患者中真实世界的治疗模式与疗效：ESME-MBC队列研究

ESMO Open
IF8.3
2025-09-170
PREAI
R. Varnier; D. Pérol; W. Jacot; A. Mailliez; V. Diéras; F. Dalenc; A. Gonçalves; C. Levy; M. Arnedos; J.-S. Frenel; C. Bailleux; V. Massard; E. Brain; B. Sauterey; A.-M. Savoye; L. Bosquet; J.-C. Thery; T. Petit; T. Bachelot; T. Grinda; I. Ray-Coquard
Compression therapy with surgical gloves compared to cold therapy with frozen gloves in preventing paclitaxel-induced peripheral neuropathy: Results from the prospective ELEGANT trial in patients with breast cancer

与使用冷冻手套的冷疗法相比，使用手术手套的加压疗法预防紫杉醇诱导的周围神经病变：来自乳腺癌患者前瞻性ELEGANT试验的结果

European Journal of Cancer
IF7.1
2025-09-120
PRE
Brunhilde Hanvic; Aurélia Joureau-Chabert; Yaëlle Ouldbey; Philippe Toussaint; Emilie Chanel; Ellen Blanc; Pierre Heudel; Virginie Montagnier; David Pérol; Thomas Bachelot
Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial

接受伊马替尼治疗的晚期胃肠道间质瘤的二十年生存率：BFR14试验的探索性长期随访

Annals of Oncology
IF65.4
2025-05-280
OAAI
J.-Y. Blay; Q. Devin; M. Toulmonde; A. Dufresne; N. Penel; A. Adenis; M. Rios; F. Bertucci; F. Duffaud; N. Firmin; T. Valentin; E. Bompas; O. Collard; M. Pracht; A. Hervieu; B. Verret; I. Ray-Coquard; P. Cassier; C. Henon; D. Perol; A. Italiano; S. Chabaud; A. Le Cesne
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse

6年与3年伊马替尼辅助治疗局部GIST复发风险高的患者的随机研究

ANNALS OF ONCOLOGY
IF65.4
2024-12-016
OAAI
Blay, J. -y.; Schiffler, C.; Bouche, O.; Brahmi, M.; Duffaud, F.; Toulmonde, M.; Landi, B.; Lahlou, W.; Pannier, D.; Bompas, E.; Bertucci, F.; Chaigneau, L.; Collard, O.; Pracht, M.; Henon, C.; Ray-Coquard, I.; Armoun, K.; Salas, S.; Spalato-Ceruso, M.; Adenis, A.; Verret, B.; Penel, N.; Moreau-Bachelard, C.; Italiano, A.; Dufresne, A.; Metzger, S.; Chabaud, S.; Perol, D.; Le Cesne, A.
Precision immuno-oncology for advanced non-small cell lung cancer (NSCLC) patients with PD-(L)1 inhibitors resistance (PIONeeR): A phase Ib/IIa clinical trial targeting identified resistance pathways

针对经PD-(L)1抑制剂治疗失败的晚期非小细胞肺癌（NSCLC）患者的精准免疫肿瘤学研究（PIONeeR）：一项靶向已知耐药通路的Ib/IIa期临床试验

ANNALS OF ONCOLOGY
IF65.4
2024-09-012
PRE
Tomasini, P.; Cropet, C.; Jeanson, A.; Perol, M.; Mazieres, J.; Fontaine, C.; Rabeau, A.; Meurer, M.; Greillier, L.; Le Ray, M.; Laborde, L.; Cohen, A.; Martin, V.; Roumieux, M.; Monville, F.; Vivier, E.; Perol, D.; Chabaud, S.; Barlesi, F.
LENVAGIST: A multicentre, comparative, placebo (P)-controlled, double-blinded, phase II study of the efficacy of Lenvatinib (L) in patients with advanced GIST after failure of imatinib and sunitinib

LENVAGIST：一项多中心、比较性、安慰剂（P）对照、双盲、II期研究，旨在评估在伊马替尼和舒尼替尼治疗失败的晚期GIST患者中伦伐替尼（L）的疗效。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Le Cesne, A.; Cropet, C.; Brahmi, M.; Bahleda, R.; Bompas, E.; Valentin, T.; Hervieu, A.; Bouche, O.; Dufresne, A.; Toulmonde, M.; Bourcier, K.; Duffaud, F.; Pracht, M.; Bertucci, F.; Lebellec, L.; Italiano, A.; Henon, C.; Gautier, J.; Perol, D.; Blay, J-Y.
Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab (D) combined with weekly paclitaxel carboplatin in 1st-line in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible to cisplatin

多中心II期FRAIL-IMMUNE试验结果，评估了度伐利尤单抗（D）联合每周给药的紫杉醇卡铂在一线治疗中，对于不符合顺铂使用条件的复发性/转移性头颈鳞状细胞癌（R/M SCCHN）患者的有效性与安全性。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Fayette, J.; Cropet, C.; Gautier, J.; Toullec, C.; Vinches, M.; Burgy, M.; Iacob, M.; Kaminsky-Forrett, M-C.; Salas, S.; Linot, B.; Champagnac, A.; Sondarjee, I.; Pechery, A.; Perol, D.; Bourhis, J.
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO
EUROPEAN JOURNAL OF CANCER
IF7.1
2024-09-010
PRE
Blay, Jean-Yves; Penel, Nicolas; Toulmonde, Maud; Valentin, Thibaud; Chaigneau, Loic; Rios, Maria; Saada-Bouzid, Esma; Firmin, Nelly; Bertucci, Francois; Marec-Berard, Perrine; Ray-Coquard, Isabelle; Lervat, Cyril; Rolland, Frederic; Thyss, Antoine; Conroy, Thierry; Brahmi, Mehdi; Dufresne, Armelle; Merrouche, Yacine; Brunat-Mentigny, Maud; Biron, Pierre; Bompas, Emmanuelle; Perol, David

研究方向

暂未获取到该数据
J
Jean‐Yves Blay
H 指数:158论文数:2,396被引数:9.5万
S
Sylvie Chabaud
H 指数:46论文数:367被引数:1.0万
O
Olivier Trédan
H 指数:55论文数:558被引数:1.7万
I
Isabelle Ray‐Coquard
H 指数:103论文数:1,069被引数:4.3万
T
Thomas Bachelot
H 指数:65论文数:556被引数:2.4万
P
Philippe A. Cassier
H 指数:60论文数:541被引数:1.6万
P
Pierre-Étienne Heudel
H 指数:30论文数:212被引数:2,970
C
Claire Cropet
H 指数:31论文数:150被引数:5,289
S
Suzette Delaloge
H 指数:88论文数:825被引数:3.6万
F
François Bertucci
H 指数:95论文数:1,366被引数:3.3万